This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.